The first matrix metalloproteinase (MMP) was discovered in 1962 from the tail of a tadpole by
its ability to degrade collagen. As their name suggests, matrix metalloproteinases are …

Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are
chronic, progressive, immune-mediated diseases of adults and children that have no cure …

Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammation of the
gastrointestinal tract with a highly heterogeneous presentation. It has a relapsing and …

Outcomes for patients starting a new treatment for inflammatory bowel disease are
characterized by uncertainty of treatment response. Although it is natural to hope that new …

Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat
inflammatory bowel disease (IBD) in the clinical practice. In this review, the principal …

Proposed treatment targets for the management of inflammatory bowel disease (IBD) have
moved beyond symptomatic improvement towards more objective end points, such as …

Objective IBD therapies and treatments are evolving to deeper levels of remission.
Molecular measures of disease may augment current endpoints including the potential for …

Background & Aims End points to determine the efficacy and safety of medical therapies for
Crohn's disease (CD) and ulcerative colitis (UC) are evolving. Given the heterogeneity in …

Background Inflammatory bowel disease (IBD) follows a heterogenous disease course and
predicting a patient's prognosis is challenging. There is a wide burden of illness in IBD and …

Abstract Background and Aims Endoscopy and the use of faecal calprotectin [faecal CP] are
among the least-favoured methods for assessing disease activity by inflammatory bowel …